---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-248678"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:25:12.025168+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nurix Therapeutics files $300M at-the-market stock offering via Piper Sandler

## Summary
- Amendment No.2 to Equity Distribution Agreement authorizes up to $300M aggregate gross offering price of common stock in ATM offerings.
- Piper Sandler receives up to 3.0% sales commission on gross proceeds; expenses reimbursed up to $50K for this amendment.
- Offering uses existing automatic shelf registration statement (File No. 333-280117) and prospectus supplement dated Oct 31, 2024.
- No specific use of proceeds disclosed in the filing; proceeds will be net of commissions and expenses.

## SEC filing metadata
- accession: 0001193125-24-248678
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000119312524248678/0001193125-24-248678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000119312524248678/d904494d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-248678
- JSON: https://secwatch.observer/filing/0001193125-24-248678.json
- Plain text: https://secwatch.observer/filing/0001193125-24-248678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.